03.06.2025 15:00:04
|
EQS-News: Evotec SE: Results of the Annual General Meeting 2025
EQS-News: EVOTEC SE
/ Key word(s): AGM/EGM
This year’s AGM was held under the topic “Pioneering Drug Discovery” and led by the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich. Chief Executive Officer Dr Christian Wojczewski presented to the Company’s shareholders an update and outlook of Evotec’s strategic, scientific, and technological developments, as well as the Company’s business performance and commitment to a sustainable growth strategy. Furthermore, the two new Management Board members Aurélie Dalbiez (Chief People Officer) and Paul Hitchin (Chief Financial Officer), introduced themselves to the shareholders. Most agenda items were adopted with great majority by the Company’s shareholders. Current and former Management Board and Supervisory Board members were discharged of liability for the 2024 financial year. Likewise, the presented Remuneration Report 2024 of Evotec SE received the majority approval of the shareholders. The Annual General Meeting 2025 also voted for amending the Articles of Association to renew the option of holding virtual general meetings as well as for the resolution on modifying the Share Performance Plan 2022 and the approval of the remuneration system for the Executive Board members. As well the appointment of BDO AG Wirtschaftsprüfungsgesellschaft, Hamburg, as auditors for the fiscal year 2025 was confirmed. In total, 46,45% of the registered share capital was represented at today’s Annual General Meeting. More information on the Company’s Annual General Meeting including the voting results on all agenda items can be found on the Company’s website at https://www.evotec.com/en/investor-relations/annual-general-meeting shortly. About Evotec SE Forward-looking-statements
For further information, please contact: Investor Relations Volker Braun
03.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | info@evotec.com |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 2149952 |
End of News | EQS News Service |
|
2149952 03.06.2025 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu EVOTEC SEmehr Nachrichten
07:29 |
Gute Stimmung in Frankfurt: Anleger lassen TecDAX zum Handelsstart steigen (finanzen.at) | |
07:29 |
Mittwochshandel in Frankfurt: MDAX zum Handelsstart mit Zuschlägen (finanzen.at) | |
10.06.25 |
Börse Frankfurt: TecDAX liegt am Dienstagnachmittag im Minus (finanzen.at) | |
10.06.25 |
Angespannte Stimmung in Frankfurt: TecDAX sackt zum Handelsstart ab (finanzen.at) | |
09.06.25 |
TecDAX aktuell: TecDAX notiert am Montagnachmittag im Minus (finanzen.at) | |
09.06.25 |
Optimismus in Frankfurt: MDAX bewegt sich am Nachmittag im Plus (finanzen.at) | |
09.06.25 |
Verluste in Frankfurt: TecDAX notiert am Mittag im Minus (finanzen.at) | |
09.06.25 |
Börse Frankfurt: MDAX am Mittag mit Verschnaufpause (finanzen.at) |
Analysen zu EVOTEC SEmehr Analysen
15.05.25 | EVOTEC Outperform | RBC Capital Markets | |
07.05.25 | EVOTEC Hold | Deutsche Bank AG | |
06.05.25 | EVOTEC Buy | Warburg Research | |
06.05.25 | EVOTEC Outperform | RBC Capital Markets | |
24.04.25 | EVOTEC Hold | Deutsche Bank AG |